[Federal Register Volume 67, Number 183 (Friday, September 20, 2002)]
[Notices]
[Pages 59295-59296]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-23875]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

New Tumor Suppressor Gene, p28ING5

Dr. Curtis C. Harris et al. (NCI)
DHHS Reference No. E-300-01/0 filed January 23, 2001
Licensing Contact: Catherine Joyce; 301/496-7735 ext. 258; e-mail: 
[email protected]

    This technology pertains to the discovery of a new member of the 
ING (inhibitor growth) family of putative tumor suppressor genes, 
p28ING5. p28ING5 was identified by homology to the tumor suppressor 
gene p33ING1. Over-expression of the ING5 protein causes cell cycle 
arrest in human cancer cell lines and ING5 expression varies between 
cancer cell lines. Detection of ING5 gene or protein expression could 
potentially be used for cancer diagnosis and ING5 could be used as a 
medicant.
    The above-mentioned invention is available for licensing on an 
exclusive or non-exclusive basis.

HGC-1, A Gene Encoding a Member of the Olfactomedin-Related Protein 
Family

Griffin P. Rodgers, Wen-Li Liu, Jiachang Zhang (NIDDK)
U.S. Provisional Patent Application 60/338,759 (E-166-01/0) filed 
December 7, 2001
Licensing Contact: Brenda Hefti; 301/496-7736 ext. 206; e-mail: 
[email protected]

    The current technology embodies a newly identified gene, Human 
Granulocyte Colony-Stimulating Factor-Stimulated-Clone-1 (hGC-1) that 
has been cloned and characterized, and its protein sequence has been 
deduced. The gene is expressed in the bone marrow, prostate, small 
intestine, colon, and stomach, and has been mapped to chromosome 13 in 
a region that contains a tumor suppressor gene cluster. The gene is 
found to be selectively present in normal human myeloid lineage cells 
and is believed to play a role in allowing lymphocytes to differentiate 
properly. It is believed that the gene may be used as a selective 
marker for human prostate cancer, multiple myeloma, B-cell chronic 
lymphocytic leukemia and other types of cancer and can be used 
diagnostically as well as in therapeutic screening activities.

Modulating IL-13 Activity Using Mutated Il-13 Molecules That Are 
Antagonists or Agonists of IL-13

R. Puri, Y. Oshima, and B. Joshi (FDA)
PCT Application PCT/US00/31044 (E-032-00/2) filed November 10, 2000, 
and claiming priority to a U.S. Provisional application filed November 
11, 1999
Licensing Contact: Brenda Hefti; 301/496-7736 ext. 206; e-mail: 
[email protected]

    The present invention provides antagonists and agonists of IL-13 
activity. The antagonists can be used to reduce or end symptoms in 
conditions, such as asthma, allergic rhinitis, atopic dermatitis, 
parasitic infections, pulmonary fibrosis, and others in which

[[Page 59296]]

IL-13 is an initiator, mediator or enhancer of the abnormal state. The 
agonists can also be used as reagents in the maturation of monocytes 
into dendritic cells, or to pre-treat bone marrow stem cell donors to 
reduce GVH disease. The antagonists can be used to slow the growth of 
cells in cancers for which IL-13 is an autocrine growth factor.
    This invention also claims IL-13 receptor binding molecules with 
affinity for the IL-13 receptor at least three times greater than that 
exhibited by wild type IL-13. Finally, this invention claims methods 
and compositions for specifically delivering an effector molecule to a 
tumor cell by chimeric molecules comprising the effector molecule 
(plant or bacterial toxin, chemotherapeutic agents or antibiotics) and 
an IL-13 receptor binding molecule (antagonists or agonists), and 
pharmaceutical compositions thereof.

    Dated: September 12, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 02-23875 Filed 9-19-02; 8:45 am]
BILLING CODE 4140-01-P